Try the modernized ClinicalTrials.gov beta website. Learn more about the modernization effort.
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis (OUTCOMS)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04873492
Recruitment Status : Recruiting
First Posted : May 5, 2021
Last Update Posted : May 5, 2021
Sponsor:
Information provided by (Responsible Party):
Nantes University Hospital

Brief Summary:
MS is a heterogeneous disease either in its response to treatment or clinical manifestation. Indeed, the natural history of MS is varying from a benign condition to a devastating and rapidly incapacitating disease. Clinical heterogeneity could also be cellular and / or molecular. The aim is to identify from OMIC analyses, at the early stage of the disease, differentially expressed molecules and / or cell subpopulations derived from CD8 + T lymphocytes and / or CD4 + T lymphocytes and / or B lymphocytes and monocytes from patients with aggressive versus non-aggressive, compared to a cohort of healthy controls

Condition or disease Intervention/treatment Phase
Multiple Sclerosis Other: Biological sample collection Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 130 participants
Allocation: Non-Randomized
Intervention Model: Parallel Assignment
Intervention Model Description: The study model consists of two cohorts, the first one or "learning cohort" includes a group of health volunteers and 2 groups of MS patients from who clinical outcome (aggressive vs non-aggressive) is already known based on clinical follow up since first event. Clinical data and blood sample have been already collected and are available from OFSEP (Observatoire français de la Sclérose en plaques). Blood will be analyzed to characterize transcriptomic, epigenomic, genomic immune cells features to discover predictive markers of clinical outcome. The second cohort or "validation cohort" consists of MS patients enrolled after their first event and followed for maximum 2-years until the determination of their clinical outcome. Blood will be collected after their first event and used in FACS to classified the patients based on molecule of interest discover thanks to learning cohort and predict clinical outcome.
Masking: None (Open Label)
Masking Description: NA/NO
Primary Purpose: Basic Science
Official Title: From Genetics to Transcriptomics to Unravel the Mechanisms Behind a Poor Outcome in Multiple Sclerosis
Actual Study Start Date : March 1, 2021
Estimated Primary Completion Date : September 1, 2024
Estimated Study Completion Date : September 1, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Retrospective Aggressive MS patients
Patients from who the clinical outcome is already known and classified as poor based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
Other: Biological sample collection
Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.

Retrospective Non Aggressive MS patient
Patient from who the clinical outcome is already known and classified as non-aggressive based on study definition detailed in inclusion criteria (retrospective arm). Blood sample collected after first event is available and used to characterize OMIC profile of T and B cells involve in MS.
Other: Biological sample collection
Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.

Healthy volunteers
Prospective arm use as comparator.
Other: Biological sample collection
Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.

Prospective MS patients
MS patients from who the clinical outcome will be established at the end of the follow up. Blood sample will be collected after the first event to validate molecules of interest from OMIC results by using FACS a different technology and classify MS patient.
Other: Biological sample collection
Venous blood sample will be collected from patients belonging to validation cohort and healthy volunteers at baseline resulting in 90 Ml EDTA tube and 10 ml serum tube. Approximately 100 ml will be collected. optional saliva and stool collection will be performed.




Primary Outcome Measures :
  1. Bulk RNA-sequencing [ Time Frame: Blood sample collection within 6 months after first inflammatory event for MS patients and at inclusion for healthy volunteers. ]
    Transcriptional profile of T and B cells in aggressive and non-aggressive MS and healthy volunteers. Measurement of gene expression of naïve and memory CD4+ and CD8+ T and B cell. Comparison of these expression level between MS patients with aggressive and non-aggressive form and healthy volunteers.


Secondary Outcome Measures :
  1. Single RNA sequencing [ Time Frame: Blood sample collection within 6 months after first inflammatory event. ]
    Single cell transcriptomics of T and B cells in order to identify by clustering, sub populations within these cells based on gene expression and associated to poor pronostic.

  2. Association of genetic sequence variation from whole genome sequencing with gene expression profile via Bulk RNA-seq [ Time Frame: Blood sample collection within 6 months after first inflammatory event. ]
    Add genetic variant analyzes to RNA seq analyses related to MS 1) Identify eQTL. 2 Impute SNPs result to calculate MS Genetic Burden (MSGB) a polygenic risk score of MS computed based on a weighted scoring algorithm using independent MS-SNPs.

  3. Association of transcriptomic variation with DNA methylation [ Time Frame: Blood sample collection within 6 months after first inflammatory event. ]
    Add Analyzes of gene expression regulation throughout DNA methylation of CpG sites to RNA seq analyses related to MS.

  4. OMIC integration [ Time Frame: Blood sample collection within 6 months after first inflammatory event. ]
    Developing machine learning method to combine genomic, epigenomic transcriptomic and clinical data to pinpoint genes of interest particularly involved in aggressive MS outcomes.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria :

Common criteria for retrospective MS patients:

  • Patients aged 18 years or older
  • Clinical isolated syndrome (CIS) with or without dissemination in space
  • Patients affiliated to an appropriate health insurance

Criteria for Aggressive MS group

• Start of a 2nd line therapy within the two years following the CIS

Criteria for Non aggressive MS group

  • No conversion according to McDonald criteria from clinical isolated syndrome to multiple sclerosis within 2 years or
  • Conversion based to McDonald criteria treated or not with first line disease modifying therapy within 2 years.
  • Have a minimum of least 2 years of follow-up.

Healthy volunteers

  • Aged 18 years or older
  • No history of clinically isolated syndrome or MS

Pairing criteria :

  • Age +/- 5 years
  • Sex

Prospective MS Patients

  • Patients aged 18 years or older
  • Clinical isolated syndrome (CIS) with or without dissemination in space
  • Patients affiliated to an appropriate health insurance

Exclusion Criteria :

  • Ongoing participation to a another study
  • Refusal to genetic analyses
  • Immunosuppressive drug at the time of blood collection
  • Adults under a legal protection regime (guardianship, trusteeship, judicial safeguard)
  • Pregnancy

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04873492


Contacts
Layout table for location contacts
Contact: David LAPLAUD, PhD 33 2 40 16 52 00 david.laplaud@chu-nantes.fr

Locations
Layout table for location information
France
Nantes University Hospital Recruiting
Nantes, Loire-Atlantique, France, 44093
Contact: David LAPLAUD, Phd    33240165200    david.laplaud@chu-nantes.fr   
Sponsors and Collaborators
Nantes University Hospital
Layout table for additonal information
Responsible Party: Nantes University Hospital
ClinicalTrials.gov Identifier: NCT04873492    
Other Study ID Numbers: RC20_0404
First Posted: May 5, 2021    Key Record Dates
Last Update Posted: May 5, 2021
Last Verified: April 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Multiple Sclerosis
Sclerosis
Pathologic Processes
Demyelinating Autoimmune Diseases, CNS
Autoimmune Diseases of the Nervous System
Nervous System Diseases
Demyelinating Diseases
Autoimmune Diseases
Immune System Diseases